[go: up one dir, main page]

NO20074913L - Unit dosage forms of temozolomide - Google Patents

Unit dosage forms of temozolomide

Info

Publication number
NO20074913L
NO20074913L NO20074913A NO20074913A NO20074913L NO 20074913 L NO20074913 L NO 20074913L NO 20074913 A NO20074913 A NO 20074913A NO 20074913 A NO20074913 A NO 20074913A NO 20074913 L NO20074913 L NO 20074913L
Authority
NO
Norway
Prior art keywords
dosage forms
unit dosage
temozolomide
relates
patient
Prior art date
Application number
NO20074913A
Other languages
Norwegian (no)
Inventor
Jacqueline Rose Bersch
Mark Manzo
Sumant Ramachandra
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20074913L publication Critical patent/NO20074913L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Denne oppfinnelsen vedrører enhetsdoseringsformer av temozolomid. Disse enhetsdoseringsformene er spesielt velegnet for reduksjon av pillebelastningen og forbedring av pasientaksept. Oppfinnelsen vedrører også fremgangsmåter for å behandle proliferative forstyrrelser hos en pasient med disse enhetsdoseringsformene. Oppfinnelsen vedrører i tillegg sett som omfatter disse doseringsformene.This invention relates to unit dosage forms of temozolomide. These unit dosage forms are particularly suitable for reducing pill loading and improving patient acceptance. The invention also relates to methods for treating proliferative disorders in a patient with these unit dosage forms. The invention also relates to sets comprising these dosage forms.

NO20074913A 2006-06-26 2007-09-27 Unit dosage forms of temozolomide NO20074913L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81662306P 2006-06-26 2006-06-26
PCT/US2007/014761 WO2008002544A2 (en) 2006-06-26 2007-06-25 Unit dosage forms of temozolomide

Publications (1)

Publication Number Publication Date
NO20074913L true NO20074913L (en) 2009-03-26

Family

ID=38704663

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074913A NO20074913L (en) 2006-06-26 2007-09-27 Unit dosage forms of temozolomide

Country Status (13)

Country Link
EP (1) EP1901740A2 (en)
JP (1) JP2008534692A (en)
KR (2) KR20080015777A (en)
CN (1) CN101309686A (en)
AR (1) AR061618A1 (en)
AU (1) AU2007221979A1 (en)
BR (1) BRPI0702847A (en)
CA (1) CA2610439A1 (en)
CL (1) CL2007001864A1 (en)
NO (1) NO20074913L (en)
TW (1) TWI326598B (en)
WO (1) WO2008002544A2 (en)
ZA (1) ZA200708280B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526038B (en) * 2011-01-12 2013-09-11 北京人福军威医药技术开发有限公司 Temozolomide brain-targeting pharmaceutical composition and application thereof
WO2017165266A1 (en) * 2016-03-21 2017-09-28 Duke University Sequential anti-cancer treatment
WO2018167627A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of anti-neoplastic alkylating agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1345240A (en) * 1999-03-30 2002-04-17 先灵公司 Improved cancer treatment with temozolomide
EP1830845A2 (en) * 2004-11-09 2007-09-12 Shering Corporation Improved dosing regimen of temozolomide for treating cancer based on the patient's mgmt level

Also Published As

Publication number Publication date
WO2008002544A2 (en) 2008-01-03
CA2610439A1 (en) 2007-12-26
WO2008002544A3 (en) 2008-02-07
KR20100055543A (en) 2010-05-26
JP2008534692A (en) 2008-08-28
EP1901740A2 (en) 2008-03-26
KR20080015777A (en) 2008-02-20
AR061618A1 (en) 2008-09-10
AU2007221979A9 (en) 2008-01-10
CL2007001864A1 (en) 2008-02-08
AU2007221979A1 (en) 2008-01-10
TWI326598B (en) 2010-07-01
ZA200708280B (en) 2009-03-25
TW200808803A (en) 2008-02-16
BRPI0702847A (en) 2008-04-01
CN101309686A (en) 2008-11-19

Similar Documents

Publication Publication Date Title
NO20083202L (en) ANG2 and VEFG inhibitor combinations
NO20084341L (en) Use of DPP-IV inhibitors
NZ609280A (en) Method for treatment of constipation-predominant irritable bowel syndrome
PH12012500916B1 (en) Treatments for gastrointestinal disorders
MX2010006823A (en) Methods for the treatment of gout.
MY204500A (en) Dosing regimen associated with long acting injectable paliperidone esters
NZ592786A (en) Methods and compositions for treating complement-associated disorders using eculizumab
AU2013299841A8 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
NO20074130L (en) Treatment Progress Mate
MX2010009724A (en) Methods of treating inflammatory pain.
MY161656A (en) Therapeutic use of diaminophenothiazines
PT2073811E (en) Kinase inhibitors useful for the treatment of myeloproliferative diseases and other proliferative diseases
WO2009086072A3 (en) Therapy of rituximab-refractory rheumatoid arthritis patients
EA201000865A1 (en) COMBINATION OF PROTEINTHYROSINPHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE INTENDED FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISTURBANCES
EA201101117A1 (en) DPP-4 INHIBITORS FOR THE TREATMENT OF DIABETES IN CHILDREN
WO2008031551A3 (en) Non-neuroendocrine cancer therapy
MX2008011633A (en) Aminoquinolones as gsk-3 inhibitors.
EA201070609A1 (en) METHODS OF TREATING OBESITY AND ASSOCIATED WITH OBESITY DISEASES AND DISORDERS
WO2010014595A3 (en) Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
MX2009006327A (en) Heterocycle compounds and methods of use thereof.
WO2007058990A3 (en) Therapy using cytokine inhibitors
NZ608813A (en) Treatment of myocardial infarction using tgf - beta antagonists
ZA201005905B (en) Methods,dosage forms,and kits for administering ziprasidone without food
MX2009004134A (en) Treatment of demyelinating disorders.
MX2010002667A (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application